Cullinan Therapeutics, Inc. (CGEM) — SEC Filings
Cullinan Therapeutics, Inc. (CGEM) — 44 SEC filings. Latest: 10-Q (May 7, 2026). Includes 15 8-K, 8 SC 13G/A, 7 10-Q.
View Cullinan Therapeutics, Inc. on SEC EDGAR
Overview
Cullinan Therapeutics, Inc. (CGEM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-3ASR filed on Apr 28, 2026: Cullinan Therapeutics, Inc. filed an S-3ASR on April 28, 2026, which is an automatic shelf registration statement for well-known seasoned issuers. This filing allows the company to efficiently register securities for future offerings without needing to file a new registration statement for each offe
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Cullinan Therapeutics, Inc. is neutral.
Filing Type Overview
Cullinan Therapeutics, Inc. (CGEM) has filed 7 10-Q, 15 8-K, 1 S-3ASR, 1 DEFA14A, 1 ARS, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 6 SC 13G, 1 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of CGEM's 26 recent filings, 2 were flagged as high-risk, 6 as medium-risk, and 18 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$169.166M |
| Cash Position | $475.5M |
| Total Assets | $484.126M |
Key Executives
- Mary Kay Fenton
- Anne-Marie Martin
- David Meek
- Jennifer Michaelson
- Patrick J. O'Brien
- Jeffrey W. Allen
Industry Context
Cullinan Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focused on developing novel therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success is often driven by innovation, clinical trial outcomes, and the ability to secure substantial funding for pipeline advancement.
Top Tags
sec-filing (7) · biotech (7) · Biotechnology (4) · 10-Q (4) · corporate-filing (3) · corporate-governance (3) · corporate-update (3) · financials (3) · annual-report (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| File Number | 333-295363 | SEC registration file number for this S-3ASR |
| Document Size (ARS PDF) | 1637880 | Size of the main annual report document in bytes. |
| Document Size (Text File) | 2257525 | Size of the complete submission text file in bytes. |
| Net Loss | $169.166M | Increased 41.06% for the nine months ended September 30, 2025, from $119.928M in 2024. |
| Research and Development Expenses | $144.457M | Increased 41.04% for the nine months ended September 30, 2025, from $102.411M in 2024. |
| Cash, Cash Equivalents, and Investments | $475.5M | Sufficient to fund operations through the next twelve months from September 30, 2025. |
| Total Assets | $484.126M | Decreased from $621.824M at December 31, 2024, indicating asset utilization or reduction. |
| Common Stock Shares Outstanding | 59,076,259 | As of October 31, 2025, reflecting slight increase from 58,510,610 at December 31, 2024. |
| SEC File Number | 001-39856 | Identifies the company's filing with the SEC |
| IRS Employer Identification No. | 81-3879991 | Company's tax identification number |
| Revenue | $0 | for the three and six months ended June 30, 2025, indicating clinical-stage status |
| Research and Development Expense | $45.1M | for the three months ended June 30, 2025, driven by pipeline advancement |
| General and Administrative Expense | $10.2M | for the three months ended June 30, 2025 |
| Reporting Period End | 2025-03-31 | This is the end date for the financial reporting period covered by the 10-Q. |
| Filing Date | 2025-05-08 | This is the date the 10-Q was officially filed with the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cullinan Therapeutics, Inc. (CGEM)?
Cullinan Therapeutics, Inc. has 44 recent SEC filings from Jan 2024 to May 2026, including 15 8-K, 8 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CGEM filings?
Across 44 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 40 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Cullinan Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cullinan Therapeutics, Inc. (CGEM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cullinan Therapeutics, Inc.?
Key financial highlights from Cullinan Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CGEM?
The investment thesis for CGEM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cullinan Therapeutics, Inc.?
Key executives identified across Cullinan Therapeutics, Inc.'s filings include Mary Kay Fenton, Anne-Marie Martin, David Meek, Jennifer Michaelson, Patrick J. O'Brien and 1 others.
What are the main risk factors for Cullinan Therapeutics, Inc. stock?
Of CGEM's 26 assessed filings, 2 were flagged high-risk, 6 medium-risk, and 18 low-risk.
What are recent predictions and forward guidance from Cullinan Therapeutics, Inc.?
Forward guidance and predictions for Cullinan Therapeutics, Inc. are extracted from SEC filings as they are enriched.